Yaling Zhou

Title: Yaling Zhou: Innovator in Tumor Suppressor Gene Research

Introduction

Yaling Zhou is a prominent inventor based in Rockville, MD (US). She has made significant contributions to the field of cancer research, particularly in the discovery of tumor suppressor genes. Her work has the potential to impact diagnostic and therapeutic approaches in oncology.

Latest Patents

Yaling Zhou holds a patent for her invention titled "Human PARIS-1 Antigen and Nucleic Acids: Diagnostic and Therapeutic Uses." This patent relates to the discovery, identification, and characterization of a novel tumor suppressor gene designated PARIS-1. The invention includes nucleotide sequences of the PARIS-1 gene and amino acid sequences of its encoded protein products, as well as fragments, derivatives, and analogs thereof. Additionally, it encompasses the production of PARIS-1 proteins, fragments, and derivatives, along with antibodies specific for PARIS-1 gene products. The invention also comprises agents and compositions that can modulate the expression of PARIS-1 or its expression products to affect the proliferation of cells expressing PARIS-1. Notably, one embodiment includes agents and compounds that can slow or ablate the proliferation of prostate tumor cells.

Career Highlights

Yaling Zhou is currently associated with Northwest Biotherapeutics, Inc., where she continues her research and development efforts. Her work at the company focuses on innovative solutions for cancer treatment, leveraging her expertise in tumor suppressor genes.

Collaborations

Due to space constraints, the collaborations section will be omitted.

Conclusion

Yaling Zhou's contributions to the field of cancer research through her patent on the PARIS-1 gene exemplify her dedication to advancing medical science. Her work holds promise for improving diagnostic and therapeutic strategies in oncology.